Identification

Name
Atenolol
Accession Number
DB00335  (APRD00172)
Type
Small Molecule
Groups
Approved
Description

A cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect.

Structure
Thumb
Synonyms
  • 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol
  • 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
  • 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
  • Atenololum
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act AtenololTablet50 mgOralActavis Pharma Company2004-08-13Not applicableCanada
Act AtenololTablet100 mgOralActavis Pharma Company2004-08-13Not applicableCanada
Ag-atenololTablet100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-atenololTablet25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-atenololTablet50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
AtenololTablet100 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AtenololTablet50 mgOralPro Doc Limitee1989-12-31Not applicableCanada
AtenololTablet100 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
AtenololTablet50 mgOralSanis Health Inc2017-10-20Not applicableCanada
AtenololTablet25 mgOralSivem Pharmaceuticals Ulc2003-04-21Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atenol Tab 100mgTablet100 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo-atenol Tab 50mgTablet50 mgOralApotex Corporation1988-12-31Not applicableCanada
AtenololTablet25 mg/1OralRemedy Repack2011-04-252016-10-13Us
AtenololTablet50 mg/1OralSandoz1991-09-17Not applicableUs
AtenololTablet25 mg/1OralPreferreed Pharmaceuticals Inc.2016-08-22Not applicableUs
AtenololTablet50 mg/1OralBlenheim Pharmacal, Inc.2014-01-06Not applicableUs
AtenololTablet50 mg/1OralClinical Solutions Wholsesale1991-09-17Not applicableUs
AtenololTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2004-11-16Not applicableUs
AtenololTablet50 mg/1Oralbryant ranch prepack1991-09-17Not applicableUs
AtenololTablet25 mg/1OralMed Pharma Co., Ltd.2011-01-20Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AtenololTablet25 mg/1OralDirectrx2017-11-10Not applicableUs
International/Other Brands
Myocord (Ivax) / Normiten (Teva)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-atenidoneAtenolol (50 mg) + Chlorthalidone (25 mg)TabletOralApotex Corporation2004-08-12Not applicableCanada
Apo-atenidoneAtenolol (100 mg) + Chlorthalidone (25 mg)TabletOralApotex Corporation2004-08-12Not applicableCanada
Atenolol and ChlorthalidoneAtenolol (50 mg/1) + Chlorthalidone (25 mg/1)TabletOralPreferreed Pharmaceuticals Inc.1992-08-01Not applicableUs00591 5782 01 nlmimage10 a30451d2
Atenolol and ChlorthalidoneAtenolol (50 mg/1) + Chlorthalidone (25 mg/1)TabletOralActavis Pharma Company1992-08-01Not applicableUs
Atenolol and ChlorthalidoneAtenolol (50 mg/1) + Chlorthalidone (25 mg/1)TabletOralAidarex Pharmaceuticals LLC1992-08-01Not applicableUs
Atenolol and ChlorthalidoneAtenolol (100 mg/1) + Chlorthalidone (25 mg/1)TabletOralPhysicians Total Care, Inc.2005-05-05Not applicableUs
Atenolol and ChlorthalidoneAtenolol (100 mg/1) + Chlorthalidone (25 mg/1)TabletOralMylan Pharmaceuticals1993-10-31Not applicableUs
Atenolol and ChlorthalidoneAtenolol (50 mg/1) + Chlorthalidone (25 mg/1)TabletOralRemedy Repack2013-05-222017-01-07Us
Atenolol and ChlorthalidoneAtenolol (50 mg/1) + Chlorthalidone (25 mg/1)TabletOralNucare Pharmaceuticals, Inc.1992-08-01Not applicableUs
Atenolol and ChlorthalidoneAtenolol (100 mg/1) + Chlorthalidone (25 mg/1)TabletOralPreferreed Pharmaceuticals Inc.1992-08-01Not applicableUs
Categories
UNII
50VV3VW0TI
CAS number
29122-68-7
Weight
Average: 266.3361
Monoisotopic: 266.16304258
Chemical Formula
C14H22N2O3
InChI Key
METKIMKYRPQLGS-UHFFFAOYSA-N
InChI
InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
IUPAC Name
2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
SMILES
CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1

Pharmacology

Indication

For the management of hypertention and long-term management of patients with angina pectoris

Structured Indications
Pharmacodynamics

Atenolol, a competitive beta(1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it does not have intrinsic sympathomimetic properties or membrane-stabilizing activity. Atenolol is used alone or with chlorthalidone in the management of hypertension and edema.

Mechanism of action

Like metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptorNot AvailableHuman
Absorption

Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces.

Volume of distribution
Not Available
Protein binding

Plasma protein binding is 6-16%

Metabolism

Hepatic (minimal)

Route of elimination

Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces. Unlike propranolol or metoprolol, but like nadolol, atenolol undergoes little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion.

Half life

6-7 hours

Clearance
Not Available
Toxicity

LD50=2000-3000 mg/kg(orally in mice). Symptoms of an atenolol overdose include a slow heart beat, shortness of breath, fainting, dizziness, weakness, confusion, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Atenolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Beta-1 adrenergic receptor---(C;C) / (C;G)G > CEffect Directly StudiedPatients with this genotype have a greater reduction in blood pressure with atenolol.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Atenolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Atenolol.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Atenolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Atenolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Atenolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Atenolol.Approved
AcetohexamideAtenolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Atenolol is combined with Acetylcholine.Approved
AcetyldigitoxinAtenolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinAtenolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Atenolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Atenolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Atenolol.Experimental, Investigational
AlaproclateThe serum concentration of Atenolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Atenolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Atenolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Atenolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Atenolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Atenolol.Experimental
AlprenololAtenolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Atenolol.Approved
AmbrisentanAtenolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateAtenolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineAtenolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Atenolol is combined with Amiloride.Approved
AminophyllineAtenolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Atenolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Atenolol.Approved, Illicit
AmodiaquineThe metabolism of Atenolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Atenolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Atenolol.Approved, Investigational
AmpicillinThe bioavailability of Atenolol can be decreased when combined with Ampicillin.Approved, Vet Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Atenolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Atenolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Atenolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Atenolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Atenolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Atenolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Atenolol.Approved, Investigational
ArbutamineAtenolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Atenolol is combined with Arecoline.Experimental
ArformoterolAtenolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Atenolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Atenolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Atenolol.Approved, Investigational
AvanafilAvanafil may increase the antihypertensive activities of Atenolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Atenolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Atenolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Atenolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Atenolol.Approved, Investigational
BambuterolAtenolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Atenolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Atenolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Atenolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Atenolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Atenolol is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Atenolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Atenolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Atenolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Atenolol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Atenolol.Approved, Withdrawn
BeractantAtenolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Atenolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Atenolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Atenolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Atenolol.Experimental
BimatoprostAtenolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Atenolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Atenolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Atenolol.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atenolol.Approved
BQ-123Atenolol may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atenolol.Approved
BretyliumBretylium may increase the bradycardic activities of Atenolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Atenolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Atenolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Atenolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Atenolol.Investigational
BucindololAtenolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Atenolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Atenolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Atenolol is combined with Bumetanide.Approved
BunazosinAtenolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Atenolol.Approved, Investigational
BupranololAtenolol may increase the hypotensive activities of Bupranolol.Approved
CabergolineAtenolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Atenolol.Experimental
CafedrineAtenolol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantAtenolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Atenolol is combined with Canagliflozin.Approved
CandesartanAtenolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Atenolol is combined with Candesartan cilexetil.Approved
CandoxatrilAtenolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Atenolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Atenolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Atenolol.Approved
CarbutamideAtenolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Atenolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Atenolol is combined with Carteolol.Approved
CarvedilolAtenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Atenolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Atenolol.Approved, Investigational
CeliprololAtenolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibAtenolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Atenolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Atenolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Atenolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Atenolol.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Atenolol.Approved, Vet Approved
ChlorpropamideAtenolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Atenolol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Atenolol.Approved
CicletanineAtenolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Atenolol.Approved, Investigational
ClenbuterolAtenolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Atenolol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Atenolol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Atenolol.Approved
CloranololAtenolol may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Atenolol.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Atenolol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Atenolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Atenolol.Vet Approved
CrizotinibAtenolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineAtenolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Atenolol.Investigational
CyclopenthiazideAtenolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideAtenolol may increase the hypotensive activities of Cyclothiazide.Approved
CymarinAtenolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Atenolol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atenolol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Atenolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Atenolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Atenolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Atenolol.Approved
DelaprilAtenolol may increase the hypotensive activities of Delapril.Experimental
DemecariumDemecarium may increase the bradycardic activities of Atenolol.Approved
DeserpidineAtenolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Atenolol.Approved
DeslanosideAtenolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Atenolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Atenolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Atenolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Atenolol is combined with Diclofenamide.Approved
diethylnorspermineAtenolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Atenolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Atenolol.Approved
DigitoxinAtenolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinAtenolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Atenolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Atenolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Atenolol is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Atenolol is combined with Dinutuximab.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Atenolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Atenolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Atenolol.Experimental
DobutamineAtenolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Atenolol.Approved
DorzolamideAtenolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinAtenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atenolol.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Atenolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Atenolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
DuloxetineAtenolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Atenolol.Investigational
DyphyllineAtenolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Atenolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Atenolol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Atenolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Atenolol.Approved
EfonidipineAtenolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Atenolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatAtenolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Atenolol.Experimental
EpanololAtenolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Atenolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Atenolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Atenolol is combined with Eplerenone.Approved
EpoprostenolAtenolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Eprosartan.Approved
Ergoloid mesylateAtenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineAtenolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Atenolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Atenolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Atenolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Atenolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Atenolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
EtoperidoneThe serum concentration of Atenolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Atenolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Atenolol.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atenolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Atenolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Atenolol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Atenolol.Approved
FenoldopamAtenolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Atenolol.Approved
FenoterolAtenolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Atenolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Atenolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Atenolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Atenolol.Experimental
Ferulic acidAtenolol may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Atenolol.Approved, Investigational
FingolimodAtenolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Atenolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Atenolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Atenolol.Experimental
FluoxetineThe serum concentration of Atenolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Atenolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Atenolol.Approved, Investigational
FormoterolAtenolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Atenolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Atenolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Atenolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Atenolol.Approved
GitoformateAtenolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideAtenolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideAtenolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAtenolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAtenolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneAtenolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideAtenolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideAtenolol may increase the hypoglycemic activities of Glyburide.Approved
GlycopyrroniumThe serum concentration of Atenolol can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Atenolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Atenolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Atenolol.Approved
GuanazodineAtenolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineAtenolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
GuanoclorAtenolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzAtenolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanAtenolol may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Atenolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Atenolol.Experimental
HexamethoniumAtenolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Atenolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Atenolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Atenolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Atenolol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAtenolol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe metabolism of Atenolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Atenolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Atenolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Atenolol.Approved
IloprostIloprost may increase the hypotensive activities of Atenolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Atenolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Atenolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Atenolol.Approved
IndacaterolAtenolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Atenolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Atenolol is combined with Indapamide.Approved
IndenololAtenolol may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Atenolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Atenolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Atenolol.Withdrawn
IndoraminAtenolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanAtenolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkAtenolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Atenolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Atenolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Atenolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Atenolol.Approved
IsoetarineAtenolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Atenolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Atenolol.Approved, Investigational, Withdrawn
IsoprenalineAtenolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Atenolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Atenolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Atenolol.Approved
IvabradineAtenolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Atenolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Atenolol.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Atenolol.Approved
LabetalolAtenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineAtenolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideAtenolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CAtenolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideAtenolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostAtenolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Atenolol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Atenolol.Approved, Investigational
LercanidipineAtenolol may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Atenolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Atenolol.Approved, Investigational
LevodopaAtenolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Atenolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
LevosalbutamolAtenolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Atenolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Atenolol.Approved, Vet Approved
LinsidomineAtenolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Atenolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Atenolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Atenolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Atenolol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Atenolol.Approved, Investigational
LucinactantAtenolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumacaftorThe serum concentration of Atenolol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Atenolol.Approved, Investigational
MacitentanAtenolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Atenolol.Approved
MalathionMalathion may increase the bradycardic activities of Atenolol.Approved, Investigational
ManidipineAtenolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Atenolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Atenolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Atenolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Atenolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Atenolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Atenolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Atenolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Atenolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Atenolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Atenolol.Approved, Investigational
MetahexamideAtenolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Atenolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Atenolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Atenolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Atenolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Atenolol.Approved
MethoserpidineAtenolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Atenolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Atenolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Atenolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Atenolol.Approved, Investigational
MethylergometrineAtenolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Atenolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Atenolol.Approved
MetildigoxinAtenolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Atenolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Atenolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Atenolol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Atenolol.Approved, Investigational
MetyrosineAtenolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilAtenolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineAtenolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Atenolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Atenolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Atenolol is combined with Minoxidil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Atenolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Atenolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Atenolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Atenolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Atenolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Atenolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Atenolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
MuzolimineAtenolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Atenolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Atenolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Atenolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Atenolol.Approved
NadololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Atenolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Atenolol.Approved
NaftopidilAtenolol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atenolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Atenolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Atenolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Atenolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Atenolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Atenolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Atenolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Atenolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Atenolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Atenolol.Approved
NiguldipineAtenolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineAtenolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Atenolol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Atenolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Atenolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Atenolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Atenolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Atenolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
ObinutuzumabAtenolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Atenolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Atenolol.Approved, Investigational
OleandrinAtenolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Atenolol.Approved, Investigational
OlodaterolAtenolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Atenolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Atenolol.Approved
OmapatrilatAtenolol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineAtenolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Atenolol.Vet Approved
OuabainAtenolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Atenolol.Approved
OxprenololAtenolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Atenolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Atenolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Atenolol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Atenolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Atenolol.Approved
PargylinePargyline may increase the hypotensive activities of Atenolol.Approved
ParoxetineThe serum concentration of Atenolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Atenolol.Investigational
PasireotideAtenolol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Atenolol.Approved
PenbutololThe risk or severity of adverse effects can be increased when Atenolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Atenolol.Approved, Vet Approved
PentoliniumAtenolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Atenolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Atenolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Atenolol.Approved
PeruvosideAtenolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Atenolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Atenolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Atenolol.Approved
PhenoxybenzamineAtenolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Atenolol.Withdrawn
PhentolamineAtenolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
PhenylpropanolamineAtenolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Atenolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Atenolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Atenolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Atenolol.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Atenolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Atenolol.Approved, Investigational
PirbuterolAtenolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Atenolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Atenolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Atenolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Atenolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Atenolol.Withdrawn
Platelet Activating FactorAtenolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideAtenolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaAtenolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Atenolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Atenolol.Experimental, Investigational
PrazosinAtenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Atenolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Atenolol.Approved
ProcaterolAtenolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Atenolol.Experimental
PromazinePromazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Atenolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Atenolol.Approved, Investigational
PropafenoneThe serum concentration of Atenolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Atenolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Atenolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Atenolol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Atenolol is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Atenolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Atenolol.Experimental
ProscillaridinAtenolol may increase the bradycardic activities of Proscillaridin.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Atenolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Atenolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Atenolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Atenolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Atenolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Atenolol.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Atenolol.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Atenolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Atenolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Atenolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Atenolol.Approved
RescinnamineAtenolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Atenolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Atenolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Atenolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Atenolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Atenolol.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Atenolol.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Atenolol is combined with Riociguat.Approved
RisperidoneAtenolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineAtenolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RituximabAtenolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Atenolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Atenolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Atenolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Atenolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Atenolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Atenolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Atenolol.Withdrawn
SalbutamolAtenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Atenolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
SalmeterolAtenolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Atenolol.Approved
SaprisartanAtenolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Atenolol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Atenolol.Approved, Investigational, Vet Approved
SelexipagAtenolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Atenolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Atenolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Atenolol.Investigational
SertralineThe serum concentration of Atenolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Atenolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Atenolol.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Atenolol.Approved
SitaxentanAtenolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Atenolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Atenolol is combined with Sotalol.Approved
SpiraprilAtenolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Atenolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Atenolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Atenolol.Approved, Investigational
SufentanilAtenolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Atenolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Atenolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Atenolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Atenolol.Experimental
TacrineTacrine may increase the bradycardic activities of Atenolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Atenolol.Approved, Investigational
TalinololAtenolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinAtenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Atenolol.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Telmisartan.Approved, Investigational
TemocaprilAtenolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Atenolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Atenolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Atenolol.Vet Approved
TerazosinAtenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineAtenolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Atenolol.Approved
TerlipressinAtenolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineAtenolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Atenolol.Approved, Investigational, Withdrawn
TheodrenalineAtenolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineAtenolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Atenolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Atenolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Atenolol.Approved
ThioridazineThioridazine may increase the hypotensive activities of Atenolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Atenolol.Approved
TiboloneAtenolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenAtenolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Atenolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Atenolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Atenolol.Approved, Investigational
TolazamideAtenolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineAtenolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideAtenolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Atenolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Atenolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Atenolol.Approved
TolonidineAtenolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Atenolol.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Atenolol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Atenolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Atenolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Atenolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Atenolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Atenolol.Approved
TreprostinilAtenolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Atenolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Atenolol is combined with Triamterene.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Atenolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Atenolol.Vet Approved
TrichlormethiazideAtenolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Atenolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
TrimazosinAtenolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Atenolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Atenolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Atenolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Atenolol.Approved, Investigational
UnoprostoneAtenolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilAtenolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Atenolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Atenolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Atenolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Atenolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Atenolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Atenolol is combined with Verapamil.Approved
VilanterolAtenolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineAtenolol may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Atenolol.Approved, Investigational
VinpocetineAtenolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideAtenolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Atenolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Atenolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Atenolol can be increased when it is combined with Zimelidine.Withdrawn
ZofenoprilAtenolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Atenolol.Withdrawn
Food Interactions
  • Consult your doctor before taking large amounts of Vitamin K (Green leafy vegetables).
  • Take 30-60 minutes before meals, take at the same time each day.

References

Synthesis Reference

Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,663,607; May 16, 1972; assigned to Imperial Chemical Industries Limited, England. Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,836,671; September 17, 1974; assigned to Imperial Chemical Industries Limited, England.

US3663607
General References
Not Available
External Links
Human Metabolome Database
HMDB01924
KEGG Drug
D00235
PubChem Compound
2249
PubChem Substance
46506915
ChemSpider
2162
BindingDB
25753
ChEBI
2904
ChEMBL
CHEMBL24
Therapeutic Targets Database
DAP000482
PharmGKB
PA448499
IUPHAR
548
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Atenolol
ATC Codes
C07CB03 — Atenolol and other diureticsC07DB01 — Atenolol, thiazides and other diureticsC07FB03 — Atenolol and other antihypertensivesC07CB53 — Atenolol and other diuretics, combinationsC07BB03 — Atenolol and thiazidesC07AB03 — Atenolol
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
FDA label
Download (112 KB)
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentBlood Pressures / Hypertensive1
0RecruitingPreventionChronic Hypertension Complicating Pregnancy (Diagnosis) / Preeclampsia1
0RecruitingPreventionObesity, Morbid / Preeclampsia1
1CompletedBasic ScienceN/A - Healthy Subjects1
1CompletedTreatmentAnginal Pain / Hypertensive1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHypertensive2
1TerminatedOtherHealthy Volunteers1
1, 2TerminatedTreatmentOrthostatic Intolerance / Postural Orthostatic Tachycardia Syndrome (POTS)1
2CompletedTreatmentHypertensive2
2CompletedTreatmentMarfan Syndrome1
2RecruitingPreventionStress Disorders, Post-Traumatic1
2RecruitingTreatmentAngina Pectoris1
2, 3CompletedTreatmentHypertensive1
3CompletedPreventionCardiac Diseases1
3CompletedPreventionCardiovascular Disease (CVD) / Cerebrovascular Disorders / Heart Diseases / Hypertensive1
3CompletedTreatmentAtherosclerotic Cardiovascular Diseases / Hypertension,Essential1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
3CompletedTreatmentHypertensive2
3CompletedTreatmentLeft Ventricular Hypertrophy1
3CompletedTreatmentMarfan Syndrome3
3CompletedTreatmentMitral Valve Stenosis1
3Not Yet RecruitingTreatmentCerebral Small Vessels Disease1
3RecruitingTreatmentHemangiomas1
3RecruitingTreatmentInfantile Hemangiomas1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
3TerminatedTreatmentHemodialysis-dependent patients / Hypertensive / Left Ventricular Hypertrophy1
3Unknown StatusPreventionMarfan Syndrome1
3Unknown StatusTreatmentCardiovascular Disease (CVD)1
4Active Not RecruitingTreatmentBlood Pressures / Stroke, Ischemic1
4CompletedHealth Services ResearchHypertensive / Metabolic Syndromes1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedPreventionPerioperative Hypertension1
4CompletedSupportive CareBlood Pressures / Exercise1
4CompletedTreatmentAtherosclerosis / Endothelial Function1
4CompletedTreatmentCoronary Artery Disease / Hypertensive1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHypertensive11
4CompletedTreatmentHypertensive / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentMarfan Syndrome1
4CompletedTreatmentPost Operative Cognitive Dysfunction1
4CompletedTreatmentUntreated Essential Hypertension1
4CompletedTreatmentChronic, stable Angina pectoris1
4RecruitingTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4TerminatedTreatmentCarotid Plaques / Hypertension,Essential1
4Unknown StatusPreventionDiabetic Nephropathies1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentGeneral Surgery1
4Unknown StatusTreatmentSmall Abdominal Aortic Aneurysm1
4Unknown StatusTreatmentType 2 Diabetes Mellitus1
4Unknown StatusTreatmentChronic, stable Angina pectoris1
4WithdrawnTreatmentHypertensive1
Not AvailableActive Not RecruitingNot AvailableHealthy Volunteers1
Not AvailableActive Not RecruitingPreventionBone, Age-related / Osteoporosis, Age-Related1
Not AvailableActive Not RecruitingTreatmentHypertensive1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Cerebral Arteriosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Hypertensive1
Not AvailableCompletedPreventionCardiovascular Disease (CVD)1
Not AvailableCompletedSupportive CareOrthognathic Surgery1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentHypertensive1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentCachexia / Cancer, Advanced1
Not AvailableUnknown StatusBasic ScienceHealthy Volunteers1

Pharmacoeconomics

Manufacturers
  • Astrazeneca pharmaceuticals lp
  • Able laboratories inc
  • Apothecon sub bristol myers squibb co
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Dava pharmaceuticals inc
  • Genpharm pharmaceuticals inc
  • Ipca laboratories ltd
  • Ipr pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Northstar healthcare holdings ltd
  • Nostrum laboratories inc
  • Pliva inc
  • Sandoz inc
  • Scs pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Unique pharmaceutical laboratories
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Astrazeneca lp
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral50 mg/mg
TabletOral
TabletBuccal; Oral; Sublingual; Transmucosal
TabletOral25 mg
TabletOral100 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Atenolol powder5.14USD g
Tenormin 100 mg tablet2.28USD tablet
Tenormin 25 mg tablet1.94USD tablet
Tenormin 50 mg tablet1.52USD tablet
Atenolol 100 mg tablet1.26USD tablet
Atenolol 50 mg tablet0.85USD tablet
Atenolol 25 mg tablet0.81USD tablet
Apo-Atenol 100 mg Tablet0.6USD tablet
Co Atenolol 100 mg Tablet0.6USD tablet
Mylan-Atenolol 100 mg Tablet0.6USD tablet
Novo-Atenol 100 mg Tablet0.6USD tablet
Phl-Atenolol 100 mg Tablet0.6USD tablet
Pms-Atenolol 100 mg Tablet0.6USD tablet
Ran-Atenolol 100 mg Tablet0.6USD tablet
Ratio-Atenolol 100 mg Tablet0.6USD tablet
Sandoz Atenolol 100 mg Tablet0.6USD tablet
Apo-Atenol 50 mg Tablet0.36USD tablet
Co Atenolol 50 mg Tablet0.36USD tablet
Mylan-Atenolol 50 mg Tablet0.36USD tablet
Novo-Atenol 50 mg Tablet0.36USD tablet
Phl-Atenolol 50 mg Tablet0.36USD tablet
Pms-Atenolol 50 mg Tablet0.36USD tablet
Ran-Atenolol 50 mg Tablet0.36USD tablet
Ratio-Atenolol 50 mg Tablet0.36USD tablet
Sandoz Atenolol 50 mg Tablet0.36USD tablet
Novo-Atenol 25 mg Tablet0.18USD tablet
Pms-Atenolol 25 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)158-160Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,663,607; May 16, 1972; assigned to Imperial Chemical Industries Limited, England. Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,836,671; September 17, 1974; assigned to Imperial Chemical Industries Limited, England.
water solubility1.33E+004 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.16HANSCH,C ET AL. (1995)
Caco2 permeability-6.44ADME Research, USCD
pKa9.6MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.429 mg/mLALOGPS
logP0.57ALOGPS
logP0.43ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area84.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity73.51 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9831
Blood Brain Barrier-0.9505
Caco-2 permeable-0.7922
P-glycoprotein substrateSubstrate0.6773
P-glycoprotein inhibitor INon-inhibitor0.9446
P-glycoprotein inhibitor IINon-inhibitor0.9856
Renal organic cation transporterNon-inhibitor0.8959
CYP450 2C9 substrateNon-substrate0.8416
CYP450 2D6 substrateSubstrate0.5468
CYP450 3A4 substrateNon-substrate0.6826
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9163
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9379
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9537
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8691
BiodegradationNot ready biodegradable0.8969
Rat acute toxicity2.0932 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.996
hERG inhibition (predictor II)Non-inhibitor0.8861
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00e9-9000000000-6a38697da7945fdb1908
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-0uy0-0950000000-e882b8032954e2a624cf
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0076-4920000000-3c7f23b7695e5c4dcc4c
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0aos-9800000000-93a18f0e030605aa10aa
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01b9-6980000000-3a2af9caa0ddc645756a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0290000000-0e1f60f7eeef06627206
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-dda902f75e8d8e525d4f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-32b90aea04b68bdedbef
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-f333c3bfc9bd6c0593d4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004l-0890000000-5c0a8df3cdde41f290f2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-58fd12e8cca5ee837799
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-271732f56fff3c9ecf87
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014l-3960000000-ee2e8e341081d16f5fdb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-3900000000-ff916216d2f4fc373c18
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-007k-3900000000-7ce05e231c161678a1d9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a5a-4900000000-4d9ba2cbcfaa9a4fd7fc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-326ded7fdf97f0b34fc5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-bb7e0317c8b0c0a5abbc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014l-3960000000-7c774d4cb55b5368392a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-3900000000-dc6f8a2d1c6ae9efff3d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-007k-3900000000-f1650653e39b75e13fa3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0532-3900000000-31769a32574200bca4e2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004l-0890000000-aae1100750adfa742e9b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-bfc82de3e4f68d57fc3a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ba-7950000000-507b336f1f79bec366f2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aba-9800000000-3a08c4ef10edc4fb0bb0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-2900000000-618ffd9706a09b5a63a3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000t-2900000000-fbfd48146105ca4959d3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0980000000-1c21805f715b600204b2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0980000000-0e0a07b984863b6487b0
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004l-0890000000-0b8ed14c1fe8c5a81255
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004l-0890000000-55a81270bd88170a11fb
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-001i-0090000000-d5916c30a1b4d703c5db
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03di-0290000000-6e3398eb8fe4bbd67783
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0290000000-40359fd567f74abb7b74
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-3910000000-43ae37638a8827ea76f1
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylacetamides
Direct Parent
Phenylacetamides
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Secondary alcohols / Primary carboxylic acid amides / Amino acids and derivatives / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Organic oxides
show 2 more
Substituents
Phenylacetamide / Phenoxy compound / Phenol ether / Alkyl aryl ether / 1,2-aminoalcohol / Amino acid or derivatives / Carboxamide group / Secondary alcohol / Primary carboxylic acid amide / Carboxylic acid derivative
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid amide, ethanolamines, propanolamine (CHEBI:2904)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Schafer M, Frischkopf K, Taimor G, Piper HM, Schluter KD: Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol. 2000 Aug;279(2):C495-503. [PubMed:10913016]
  2. Brown RA, Ilg KJ, Chen AF, Ren J: Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption. Eur J Pharmacol. 2002 May 10;442(3):241-50. [PubMed:12065078]
  3. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611]
  4. Alberti C, Monopoli A, Casati C, Forlani A, Sala C, Nador B, Ongini E, Morganti A: Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists. J Cardiovasc Pharmacol. 1997 Sep;30(3):320-4. [PubMed:9300315]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Nuttall SL, Routledge HC, Kendall MJ: A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179-86. [PubMed:12795776]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
  2. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34